10-Q · May 14, 2026
Invivyd, Inc. reported a Q1 2026 revenue of $13.7 million, representing a 22% increase year-over-year from $11.3 million in Q1 2025, alongside a net loss of $41.4 million. The increase in revenue is attributed to higher…
Earnings analysis · 10-Q
IVVD earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Invivyd generated $14.285 million of second-quarter revenue and diluted EPS of $(0.14), with PEMGARDA revenue up 21% year over year. However, net loss increased to $44.4 million from $14.7 million, leaving the company…
Read full summary
Invivyd generated $14.285 million of second-quarter revenue and diluted EPS of $(0.14), with PEMGARDA revenue up 21% year over year. However, net loss increased to $44.4 million from $14.7 million, leaving the company dependent on PEMGARDA while advancing clinical programs. The most material new risks are the June 29, 2027 PEMGARDA EUA termination, the January 19, 2027 Nasdaq compliance deadline, and the loss of a potential EUA pathway for VYD2311.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.14
- Segment
- PEMGARDA: revenue grew 21% year over year; dollar segment revenue was not disclosed in the provided filing text.
What stood out
-
Revenue edged higher sequentially
Second-quarter revenue was $14.285 million and diluted EPS was $(0.14). Revenue was approximately $14 million in Q1 2026, indicating sequential growth of about 2%.
-
PEMGARDA sales grew 21%
PEMGARDA revenue grew 21% year over year, supporting continued commercial revenue while the product remains authorized under its EUA.
-
Cash runway supports key readout
Management expects $160.1 million of cash to provide runway through the DECLARATION data readout, with top-line data planned for later in Q3 2026.
-
Two clinical catalysts in Q3
DECLARATION top-line data is planned for later in Q3 2026 and LIBERTY data is anticipated in late Q3 2026, providing multiple near-term clinical catalysts.
-
Controls remained effective
Disclosure controls were concluded effective as of June 30, 2026, and management reported no material changes in internal control over financial reporting during the quarter.
What to watch
-
PEMGARDA EUA ends June 29, 2027
HHS provided advance notice on June 30, 2026 that the COVID-19 emergency declaration will terminate after a twelve-month transition period ending June 29, 2027. The PEMGARDA EUA is consequently set to terminate on June 29, 2027, unless regulatory approval is obtained beforehand.
-
Nasdaq minimum-bid compliance risk
Nasdaq notified the company on July 23, 2026 that its stock had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until January 19, 2027 to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
-
VYD2311 faces a longer approval path
Following termination of the HHS declaration, the FDA intends to decline new COVID-19 EUA requests. The company therefore would be precluded from pursuing an EUA for VYD2311 and would instead need to pursue traditional regulatory approval processes.
-
Operating losses expanded sharply
Net loss widened to $44.4 million from $14.7 million in the year-earlier period as R&D and SG&A expenses increased, despite second-quarter revenue of $14.285 million.
-
Revenue remains concentrated in PEMGARDA
PEMGARDA is the company’s first and only product candidate with regulatory authorization, and the filing states that no other product candidate has regulatory authorization or approval in any jurisdiction.
Management's outlook
No formal numeric revenue or EPS guidance was provided. Management indicated that DECLARATION top-line data is planned for later in Q3 2026, LIBERTY data is anticipated in late Q3 2026, and $160.1 million of cash is expected to provide runway through the DECLARATION data readout.
Earlier filings 4
10-K · March 5, 2026
Invivyd describes a commercial-stage strategy focused on executing the U.S. launch of PEMGARDA (EUA granted March 22, 2024) while advancing next‑generation mAb VYD2311 through a rapid REVOLUTION development pathway…
10-Q · May 15, 2025
Invivyd recorded first quarter product revenue of $11.304 million and narrowed net loss to $16.289 million (EPS -$0.14). Gross margin remained high at ~92.6% but operating loss remained large (loss from operations…
10-Q · November 9, 2023
Invivyd, Inc. reported a net loss of $39.44 million for Q3 2023, compared to a loss of $45.09 million in Q3 2022, reflecting improved operational efficiency. Cash and cash equivalents rose sharply to $181.82 million…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.